These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8681505)

  • 1. [Reduction of the Nordin index after therapy with oral alendronate in patients with postmenopausal osteoporosis].
    Busi S; Catalano A
    Clin Ter; 1995 Dec; 146(12):857-9. PubMed ID: 8681505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].
    Buffo L; Rossini M; Buoncristiano A; Girardello S; Zamberlan N; Diani F; Adami S
    Minerva Ginecol; 1996 Jun; 48(6):263-72. PubMed ID: 8927288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F; Rodoplu M
    Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate: a new bisphosphonate for the treatment of osteoporosis.
    Keen RW; Spector TD
    Br J Clin Pract; 1996 Jun; 50(4):211-7. PubMed ID: 8759568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate in postmenopausal osteoporosis.
    McGrath H
    N Engl J Med; 1996 Mar; 334(11):734; author reply 734-5. PubMed ID: 8594443
    [No Abstract]   [Full Text] [Related]  

  • 18. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimal osteoporosis strategy?].
    Scharla S; Reichenhall B
    Krankenpfl J; 2005; 43(1-3):65. PubMed ID: 15912853
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a role for a random measurement of 24-hour urine calcium excretion in the determination of calcium supplementation in osteoporotic postmenopausal women using alendronate?
    Pines A; Weisman Y; Ayalon D; Shapira I
    Gynecol Endocrinol; 2005 Jan; 20(1):45-7. PubMed ID: 15969246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.